Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.48 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273530 | 0.87 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 | |
| SCHEMBL12326834 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 | |
| SCHEMBL269614 | 0.81 | AKR1C3 (0.63) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 | |
| SCHEMBL30580504 | 0.81 | AKR1C3 (0.63) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 | |
| SCHEMBL6564101 | 0.81 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 | |
| SCHEMBL268414 | 0.80 | TDP1 (0.62) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 | |
| SCHEMBL404510 | 0.80 | MAPT (0.51) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 | |
| SCHEMBL4946199 | 0.80 | AKR1C3 (0.51) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 | |
| Potassium Ion SCHEMBL15876122 | 0.80 | AKR1C3 (0.51) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 | |
| Hydrochloric Acid SCHEMBL11462649 | 0.80 | MAOA (0.53) | ALDH1A1SMN1; SMN2AKR1C3AKR1C2AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| EP-2593435-B1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | TAIRX INC (TW) | 2016-09-07 | — | — | EP | disclosed |
| CN-103347859-B | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MANAGEMENT CORP. (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-103347859-A | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MAN CORP | 2013-10-09 | — | — | CN | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| US-4804756-A | Process for preparing 5,6-dialkoxy-4-alkyl-2(1H)-quinazolinones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-02-14 | — | — | US | disclosed |
| US-4751304-A | Process for preparing 5,6-dialkoxy-4-alkyl-2(1H)-quinazolinones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0177256-A2 | Process for preparing 5,6-dialkoxy-4-alkyl-2(1h)-quinazolinones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-04-09 | — | — | EP | disclosed |
| US-4556739-A | QUINAZOLINONE INTERMEDIATES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | ALDH1A1 1258/4885SMN1; SMN2 3441/4885AKR1C3 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.